Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―― Live and ...

Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, ...

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed ...

A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged ...

Title: A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study ...

Ascentage Pharma Group International ( ($HK:6855) ) has provided an update. Ascentage Pharma announced that it will present the latest results ...

Please provide your email address to receive an email when new articles are posted on . Higher percentages of the U.S. population live closer to clinical trial sites than they did a decade ago.

COLUMBUS, OH & SYRACUSE, N.Y.--(BUSINESS WIRE)--Deep Lens and Hematology-Oncology Associates of Central New York (HOA CNY) today announced that they have entered into a collaboration to expand the ...

SAN DIEGO, Dec. 13, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted ...